A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

NCT03435289 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions

DRUG: CPI 613 in Combination With Gemcitabine and Nab-paclitaxel

Sponsor

Atlantic Health System

Collaborators

[object Object]